

1 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

38 **Abstract**

- 71 Altered plasma levels of soluble markers that potentially could reflect changes in amyloid
- 72 processing was found in patients with persistent headache after SARS-CoV-2 vaccine and
- 73 particular in those with persistent headache after COVID-19 disease with association to
- 74 cognitive symptoms.
- 75

76 **How this study might affect research, practice or policy**

- 77 Our data point to plausible mechanism of amyloid processing and neuroinflammation in
- 78 relation to COVID-19 and SARS-CoV-2 vaccine.

- 80
- 81

82 **Introduction**

116 with persistent headaches after SARS-CoV-2 infection or vaccination, with or without

117 headache during the acute phase of COVID-19 or immediately after vaccination, have not

118 been reported.

119 In the present study, with the aim to give novel insight into the pathological

- 120 mechanisms leading to persistent headache following COVID-19 and SARS-CoV-2
- 121 vaccination, we compared plasma levels of APP, PZP, CTSL, and SAA-1 in patients with
- 122 persistent headache after SARS-CoV-2 infection or vaccination compared with levels in
- 123 healthy controls without headaches. The levels of these molecules were also related to the
- 124 presence of accompanying fatigue or cognitive symptoms, and in the COVID-19 group, the
- 125 need for hospitalization during the acute infection.
- 126

127 **Methods**

- 128 In this prospective observational cohort study performed at Norwegian neurological
- 129 departments and led by Oslo University Hospital, Oslo, Norway, clinical characteristics and
- 130 blood biomarker profiles were assessed in patients with severe headaches for a minimum of
- 131 six months after COVID-19 or SARS-CoV-2 vaccination and compared to healthy controls.
- 132 The inclusion period lasted from September 2020 to June 2023.
- 133

134 **Study population and clinical assessments of the participants**

135 The subgroup with **persistent headache after COVID-19 (n=29)** was recruited from the

136 cohort of 155 individuals aged \geq 18 years with persistent neurological symptoms 6 months

137 after COVID-19 infection in the Norwegian observational multicentre study of nervous

138 system manifestations and sequelae after COVID infection (NNC), a sub study of the

- 139 ENERGY study led by European Academy of Neurology.¹⁷ The subgroup with **persistent**
- 140 **headache after SARS-CoV-2 vaccine** (n=31) were participants in the Norwegian
- 141 observational multi-centre study CovaxHEAD: New-onset severe headache after COVID-19
- 142 vaccine (NCT05235776) a parallel study led by the same team as the NNC study collecting
- 143 comparable variables.

144 Inclusion criteria for both subgroups were age \geq 18 years and new onset severe 145 headache or severe worsening of pre-existing headache within one week after SARS-CoV-2 146 infection or vaccination. The degree of headache severity had to be so pronounced that the 147 headaches were daily or almost daily and had resulted in significant disability or sick leave 148 and still were the dominant symptom at 6-month follow-up. Exclusion criteria were short-149 lasting headaches, no follow-up assessments, or where other diagnoses were considered a

150 better explanation for their symptoms (e.g. infections including COVID-19, head trauma, or

151 somatoform disorders). Participants with COVID-19 disease who reported their headaches

- 152 starting after SARS-CoV-2 vaccination were not included. Thus, none in this COVID-19
- 153 subgroup had SARS-CoV-2 vaccine induced headache.
- 154 For both headache groups, an inclusion criterion was available plasma samples that 155 could be used in biomarker analyses. The clinical data, including the headache diagnoses, 156 were reviewed by a senior neurologist with headache expertise (AHA).
- 157 The **control group** consisted of healthy individuals (n=16) based on disease history
- 158 without migraine or any other disabling headache disorders and who had never experienced
- 159 neurological symptoms after SARS-CoV-2 vaccine or COVID-19. Additional inclusion

160 criteria in the control group were no immunological disorders or use of immunosuppressive

161 drugs. The healthy controls, consisting of 8 men and 8 women, mean age 40.6 years (SD

162 11.2), were recruited from local advertisements at Oslo University Hospital.

163 **Blood sampling protocol**

164 Peripheral venous blood was drawn into pyrogen-free blood collection tubes with

- 165 ethylenediamine tetraacetic acid (EDTA) as an anticoagulant, immediately immersed in
- 166 melting ice and centrifuged at 4° C 2500 \times *g* for 20 minutes within 60 minutes to obtain
- 167 platelet-poor plasma. The plasma samples were stored in multiple aliquots and thawed only
- 168 once.

169 **Biomarker assessments**

- 170 Plasma markers were assessed in all three groups patients with persistent headache after
- 171 COVID-19 infection (n=29), patients with persistent headache after the COVID-19 vaccine
- 172 (n=31), and healthy controls (n=16). The participants had blood samples drawn when they
- 173 were included in the study. Additionally, 6-month follow-up blood sampling was done in the
- 174 headache groups. Plasma levels of APP (Cat# DY850), PZP (Cat# DY8280-05), CTSL (Cat#
- 175 DY952), and SAA1 (Cat# DY3019-05) were measured by enzyme-linked immunosorbent
- 176 assay (ELISA) using commercially available antibodies (R&D Systems, Minneapolis, MN) in
- 177 a 384-format using a combination of a SELMA pipetting robot (Analytik Jena AG, Jena,
- 178 Germany) and a BioTek dispenser/washer (BioTek Instruments, Winooski, VT). Absorption
- 179 was read at 450 nm by using an EIA plate reader (BioTek Instruments) with wavelength
- 180 correction set to 540 nm. Intra- and inter-assay coefficients of variation for these analyses
- 181 were all <10%.
- 182

183 **Ethics approval**

184 This study was conducted in accordance with the Helsinki Declaration as revised in 2013.

185 Ethical approval for this study was obtained from The Norwegian South-Eastern Ethical

186 Committee (152727 NNC, 351097 CovaxHEAD). Written informed consent was obtained

- 187 from all subjects before inclusion into the study.
- 188

189 **Statistics**

190 Statistical Package for Social Science (IBM SPSS Inc., version 29 for Windows) was used for

191 statistical analysis. Differences in patient characteristics were tested using the Chi-square test

192 or Fisher's exact test for categorical variables, and the Mann-Whitney U test for continuous

193 variables. Prevalence of characteristics (frequency and percentages) were calculated for each

194 group. A two-sided p-value of <0.05 was deemed statistically significant.

195

196 **Results**

197 **Characteristics and headache phenotypes in the study group**

198 Demographics such as age, gender and co-morbidities are shown in Table 1. There was equal

199 age and sex distribution in both headache groups (i.e., persistent headache following COVID-

200 19 or SARS-CoV-2 vaccination, respectively) with 3 out of 4 participants being female.

201 Comorbidity of frequent diseases, such as pre-existing migraine, allergies, anxiety, and

202 depression were common in both groups. Few had cardiovascular or metabolic disorders.

203 One-third of the patients with persistent headache after COVID-19 infection was hospitalised

204 in the acute phase of the infection. In the group with a persistent headache after SARS-CoV-2

205 vaccine 17 (54.8%) reported previous COVID-19 at baseline, but importantly, without any

- 206 persistent headache after the infection (Table 1). There was a high disability among the
- 207 participants of both headache groups. More than two thirds of the participants with post
- 208 COVID-19 and more than half the participants with headache post SARS-CoV-2 vaccination
- 209 were on sick-leave due to the current symptoms at inclusion with only a modest reduction in

210 the percentages on sick-leave at 6-month follow-up (72.4 % to 65.5 % and 58.1 % to 45.2 %,

211 post COVID-19 and SARS-CoV-2 vaccination, respectively; Table 1). Cognitive symptoms

212 and fatigue were common, but not dominating (see Methods), in both headache groups (Table

 $213 - 1$).

214

215 Table 1. Demographic and clinical characteristics at inclusion

216

217 **Biomarkers in relation to post-COVID-19 headache and headache following SARS-**

218 **CoV-2 vaccination**

219 At both inclusion and after 6 months, we found a strong and persistent upregulation of APP in 220 patients with headache after COVID-19 as compared to individuals with vaccine induced 221 headache and healthy controls (Figure 1A). There was also upregulation of CTSL in patients 222 with headache after COVID-19 as compared to individuals with vaccine induced headache 223 and healthy controls at inclusion, but these differences were not seen at 6 months follow-up 224 (Figure 1B). In contrast, plasma levels of PZP were elevated in both headache groups as 225 compared to healthy controls at inclusion and after 6 months follow-up (Figure 1C). As for 226 SAA1, being a classical acute phase protein reflecting inflammation, there were no 227 differences between the two headache groups and healthy controls either at baseline or during 228 follow-up (Figure 1D). Finally, whereas post-COVID-19 symptoms have been related to 229 disease severity during the acute phase, 18 we found no differences in the actual biomarkers 230 between those who were hospitalized and those who were not hospitalized during the acute 231 phase of COVID-19 (data not shown). 232 233 **Biomarker levels in relation to associated fatigue and cognitive symptoms** 234 There was a significant upregulation of APP among participants with accompanying cognitive 235 symptoms in the group with persistent headache after COVID-19, but this pattern was not 236 seen in those with headache after SARS-CoV-2 vaccination (Figure 2). Although those with 237 fatigue also had higher levels of APP compared with those without, the difference did not 238 reach statistical significance (Figure 2). As for PZP, CTSL, there were no differences between

239 those with or without associated cognitive symptoms or fatigue, neither in the COVID-19 nor

240 the SARS-CoV-2 group (data not shown).

241

242 **Discussion**

243 Persistent headache has been reported following acute COVID-19 disease and to some degree 244 also after SARS-CoV-2 vaccination.^{1, 3} In the present study, we report higher plasma levels of

245 APP in patients with persistent headache after COVID-19 disease, but not in patients with

246 persistent headache following SARS-CoV-2 vaccination, compared to healthy controls.

247 Remarkably, elevated APP persisted at 6 months follow-up and was associated with

248 accompanying cognitive symptoms. Notably, plasma levels of PZP were higher in both

249 headache groups as compared to controls with a similar pattern after 6 months follow-up. This

250 is to the best of our knowledge, the first report that relates proteins involved in amyloid

251 formation in persistent headache following COVID-19 disease, and for PZP, also in

252 individuals with persistent headache after SARS-CoV-2 vaccination.

253 As depicted in Figure 3, our data point to plausible mechanism of serum APP and PZP 254 proteins in relation to COVID-19 and SARS-CoV-2 vaccine induced headache. In brief, APP 255 is produced by neurons and proteolysis by different secretases may produce a soluble (s) 256 fragment, sAPP, and release of the neurotoxic $\mathcal{A}\beta$ peptide. SARS-CoV-2 infection may 257 increase APP expression via the ACE2 receptor^{19, 20} and APP promotes cellular entry of the 258 virus enhancing Aβ-associated pathology.¹⁰ The Aβ peptide may accumulate and form 259 amyloid plaques²¹ leading to activation of astrocytes and microglia and promote 260 neuroinflammation by different mechanisms²² with potential effect on headache symptoms.²³ 261 Increased levels of APP is reported as marker for preclinical Alzheimer disease, 262 however, this protein biological function is beyond that of amyloid formation²⁴ and elevated 263 levels has been found in various metabolic and cardiovascular disorders.²⁵ In the present 264 study, however, few or none had such clinically verified co-morbidities. However, we found 265 significant upregulation of APP among participants with accompanying cognitive symptoms 266 in the group with persistent headache after COVID-19 compared to those without cognitive 267 symptoms. Moreover, network analyses of SARS-CoV-2 infection in brain microvascular 268 endothelial cells suggested increased expression of APP.¹⁹ In a previous study of patients with 269 COVID-19 associated neurological syndromes, signs of impaired amyloid processing was 270 found with significantly reduced soluble amyloid precursor protein in CSF from patients 271 compared to controls.²⁶ However, this study was dominated of patients with severe 272 neurological diseases such as Guillain Barre syndrome and encephalopathy and only one 273 patient was described with central pain syndrome.²⁶ Furthermore, cognitive symptoms were 274 not reported. At present, however, the reason for and the clinical consequences of the raised 275 APP in patients with persistent headache following COVID-19 disease is elusive and follow-276 up studies are clearly needed. 277 In contrast to APP, plasma levels of PZP were persistently elevated in both headache 278 groups, i.e., prolonged headache following both COVID-19 and SARS-CoV-2 vaccination. 279 The reason for this pattern is so far unclear. PZP is known to promote a beneficial 280 immunosuppression during pregnancy to avoid rejection of the foetus. More recently, 281 increased PZP levels has been found during airway infections¹² and have been suggested as a 282 marker of certain cancers.²⁷ Moreover, previous studies with mouse models have indicated 283 that APP can increase the entry of the SARS-Cov-2 virus into cells whereas PZP has been 284 described to inhibit amyloid aggregation.²⁸ Since APP was lower in the vaccine group than 285 the COVID-19 group, one intriguing hypothesis is that PZP were able to inhibit amyloid 286 aggregation at a higher degree in the vaccine group than in the COVID-19 group. However,

287 PZP has also been reported to stabilize misfolding proteins like amyloid β protein, and the

288 role of PZP in amyloid formation is still not clear.²⁸

289 The strengths of this study were the comprehensive examinations of the participants 290 done by headache specialists with precise phenotyping of the headache syndromes and the

291 strong multidisciplinary collaboration. The major limitations were the lack of CSF samples in

292 both headache groups. Moreover, we lack parallel samples from CSF and measurements of

293 the actual protein in individuals that have undergone COVID-19 and SARS-CoV-2

294 vaccination without the development of persistent headache.

295 In summary, altered plasma levels of soluble markers that potentially could reflect

296 changes in amyloid processing was found in patients with persistent headache after SARS-

297 CoV-2 vaccine and particular in those with persistent headache after COVID-19 disease with

298 association to cognitive symptoms. Future and larger studies that also include CSF samples

299 are needed to further elaborate the clinical consequences of these findings.

300

301 **Acknowledgement:** We thank Marcus Boateng for registering data and Katrine Persgård

302 Lund and Azita Rashidi for the processing of blood biomarkers.

303 **References**

304 1. Caronna E, van den Hoek TC, Bolay H, et al. Headache attributed to SARS-CoV-2 305 infection, vaccination and the impact on primary headache disorders of the COVID-19 306 pandemic: A comprehensive review. Cephalalgia 2023;43:3331024221131337. 307 2. Shen Q, Joyce EE, Ebrahimi OV, et al. COVID-19 illness severity and 2-year 308 prevalence of physical symptoms: an observational study in Iceland, Sweden, Norway and 309 Denmark. Lancet Reg Health Eur 2023;35:100756. 310 3. Atalar AC, Acarli ANO, Baykan B, et al. COVID-19 vaccination-related headache 311 showed two different clusters in the long-term course: a prospective multicenter follow-up 312 study (COVA-Head Study). J Headache Pain 2023;24:132. 313 4. Files JK, Sarkar S, Fram TR, et al. Duration of post-COVID-19 symptoms is 314 associated with sustained SARS-CoV-2-specific immune responses. JCI Insight 2021;6. 315 5. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-316 CoV-2. Nature 2021;591:639-644. 317 6. Garces KN, Cocores AN, Goadsby PJ, Monteith TS. Headache After Vaccination: An 318 Update on Recent Clinical Trials and Real-World Reporting. Curr Pain Headache Rep 319 2022;26:895-918. 320 7. Hervé CL, B.; Del Giudice, G.; Didierlaurent, AM.; Tavares Da Silva, F. . The how's 321 and what's of vaccine reactogenicity. NPJ Vaccines 2019;4. 322 8. Li HX, X.; Ren, H.; Xu, L.; Zhao, L.; Chen, X.; Long, H.; Wang, Q.; Wua, Q. Serum 323 Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis. J Infect 324 2020;80:646–655. 325 9. Orobets KS, Karamyshev AL. Amyloid Precursor Protein and Alzheimer's Disease. Int 326 J Mol Sci 2023;24. 327 10. Chen J, Chen J, Lei Z, et al. Amyloid precursor protein facilitates SARS-CoV-2 virus 328 entry into cells and enhances amyloid-beta-associated pathology in APP/PS1 mouse model of 329 Alzheimer's disease. Transl Psychiatry 2023;13:396. 330 11. Shao J, Jin Y, Shao C, Fan H, Wang X, Yang G. Serum exosomal pregnancy zone
331 protein as a promising biomarker in inflammatory bowel disease. Cell Mol Biol Lett 331 protein as a promising biomarker in inflammatory bowel disease. Cell Mol Biol Lett 332 2021;26:36. 333 12. Finch S, Shoemark A, Dicker AJ, et al. Pregnancy Zone Protein Is Associated with 334 Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in 335 Bronchiectasis. Am J Respir Crit Care Med 2019;200:992-1001. 336 13. Villar M, Urra JM, Rodriguez-Del-Rio FJ, et al. Characterization by Quantitative 337 Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 338 Symptomatology. Front Immunol 2021;12:730710. 339 14. Ijsselstijn L, Dekker LJ, Stingl C, et al. Serum levels of pregnancy zone protein are 340 elevated in presymptomatic Alzheimer's disease. J Proteome Res 2011;10:4902-4910. 341 15. Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2 342 infection in humans and humanized mice and is a promising target for new drug development. 343 Signal Transduct Target Ther 2021;6:134. 344 16. Wang H, Sang N, Zhang C, Raghupathi R, Tanzi RE, Saunders A. Cathepsin L 345 Mediates the Degradation of Novel APP C-Terminal Fragments. Biochemistry 2015;54:2806- 346 2816. 347 17. Beghi E, Moro E, Davidescu EI, et al. Comparative features and outcomes of major 348 neurological complications of COVID-19. Eur J Neurol 2023;30:413-433. 349 18. Headache Classification Committee of the International Headache Society (IHS) The 350 International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211.

351 19. Camacho RC, Alabed S, Zhou H, Chang SL. Network Meta-analysis on the Changes 352 of Amyloid Precursor Protein Expression Following SARS-CoV-2 Infection. J Neuroimmune 353 Pharmacol 2021;16:756-769. 354 20. Caradonna A, Patel T, Toleska M, Alabed S, Chang SL. Meta-Analysis of APP 355 Expression Modulated by SARS-CoV-2 Infection via the ACE2 Receptor. Int J Mol Sci 356 2022;23. 357 21. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. 358 Annu Rev Neurosci 2011;34:185-204. 359 22. Di Benedetto G, Burgaletto C, Bellanca CM, Munafo A, Bernardini R, Cantarella G. 360 Role of Microglia and Astrocytes in Alzheimer's Disease: From Neuroinflammation to $Ca(2+)$ 361 Homeostasis Dysregulation. Cells 2022;11. 362 23. Kursun O, Yemisci M, van den Maagdenberg A, Karatas H. Migraine and 363 neuroinflammation: the inflammasome perspective. J Headache Pain 2021;22:55. 364 24. Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol 365 Neurodegener 2006;1:5. 366 25. Guo Y, Wang Q, Chen S, Xu C. Functions of amyloid precursor protein in metabolic 367 diseases. Metabolism 2021;115:154454. 368 26. Ziff OJ, Ashton NJ, Mehta PR, et al. Amyloid processing in COVID-19-associated

- 369 neurological syndromes. J Neurochem 2022;161:146-157.
- 370 27. Huang J, Xu Y, Chen Y, et al. Revisiting the role of pregnancy zone protein (PZP) as a 371 cancer biomarker in the immunotherapy era. J Transl Med 2024;22:500.
- 372 28. Cater JH, Kumita JR, Zeineddine Abdallah R, et al. Human pregnancy zone protein
- 373 stabilizes misfolded proteins including preeclampsia- and Alzheimer's-associated amyloid
- 374 beta peptide. Proc Natl Acad Sci U S A 2019;116:6101-6110.

376 **Figure legends**

- 377 **Figure 1.** Plasma levels of **A.** Amyloid Precursor Protein (APP), **B**. Cathepsin L., **C.**
- 378 Pregnancy Zone Protein (PZP) and **D**. Serum Amyloid A (SAA1) in healthy controls (HC)
- 379 (n=16), participants with persistent headache after SarsCoV-2 vaccine (COvax) (n=31) and
- 380 participants with persistent headache after COVID-19 (C19) (n=29).
- 381
- 382 **Figure 2.** Plasma levels of Amyloid Precursor Protein (AAP) in relation to cognitive
- 383 symptoms and fatigue in those with persistent headache after SARS-CoV-2 vaccine (COvax)
- 384 or COVID-19 (C19).
- 385
- 386 **Figure 3.** Possible mechanisms of soluble Amyloid Precursor Protein (sAPP) and Pregnancy
- 387 Zone Protein (PZP) in relation to COVID-19 and SARS-CoV-2 vaccination associated
- 388 headache. The authors wish to acknowledge SERVIER Medical Art (www.servier.fr) for use
- 389 of their medical art kits when making the illustration in the article.

- 390 **Study funding:** Supported by Oslo University Hospital and the Southern and Eastern Norway
- 391 Regional Health Authority (2021051).
- 392 **Acknowledgement:** We thank Marcus Boateng for registering data and Katrine Persgård
- 393 Lund and Azita Rashidi with the sampling of blood biomarkers.
- 394 **Statistical Analysis:** Thor Ueland and Anne Hege Aamodt
- 395 **Disclosure**
- 396 **Conflicts of interest:** The authors report no disclosures relevant to this study.
- 397 A.H. Aamodt has received honoraria for advice or lecturing from Pfizer Allergan, Teva,
- 398 Novartis, Roche, Lundbeck and Teva and research grant from Boehringer Ingelheim.
- 399 Anne Christine Poole: lecturing, advisory boards and/or clinical studies: Abbvie, Lundbeck,
- 400 Pfizer, Novartis, Teva, Eli Lilly
- 401

